Evidence map›Paper›PMID 32634370›Full record

ReviewOpen biology2020

Core regulatory circuitries in defining cancer cell identity across the malignant spectrum.

Leila Jahangiri, Loukia Tsaprouni, Ricky M Trigg, John A Williams, Georgios V Gkoutos, Suzanne D Turner, Joao Pereira

Open access · goldAbstract readReview
In one paragraph

Review in Open biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Leila JahangiriDepartment of Life Sciences, Birmingham City University, Birmingham, UK.
Loukia TsaprouniDepartment of Life Sciences, Birmingham City University, Birmingham, UK.
Ricky M TriggDivision of Cellular and Molecular Pathology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
John A WilliamsInstitute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Georgios V GkoutosInstitute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Suzanne D TurnerDivision of Cellular and Molecular Pathology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Joao PereiraDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.
Birmingham City University · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBGlaxoSmithKline (United Kingdom) · GBHarvard University · USUniversity of Cambridge · GB

Funding

Medical Research Council
6 · The paper itself

Abstract

Gene expression programmes driving cell identity are established by tightly regulated transcription factors that auto- and cross-regulate in a feed-forward manner, forming core regulatory circuitries (CRCs). CRC transcription factors create and engage super-enhancers by recruiting acetylation writers depositing permissive H3K27ac chromatin marks. These super-enhancers are largely associated with BET proteins, including BRD4, that influence higher-order chromatin structure. The orchestration of these events triggers accessibility of RNA polymerase machinery and the imposition of lineage-specific gene expression. In cancers, CRCs drive cell identity by superimposing developmental programmes on a background of genetic alterations. Further, the establishment and maintenance of oncogenic states are reliant on CRCs that drive factors involved in tumour development. Hence, the molecular dissection of CRC components driving cell identity and cancer state can contribute to elucidating mechanisms of diversion from pre-determined developmental programmes and highlight cancer dependencies. These insights can provide valuable opportunities for identifying and re-purposing drug targets. In this article, we review the current understanding of CRCs across solid and liquid malignancies and avenues of investigation for drug development efforts. We also review techniques used to understand CRCs and elaborate the indication of discussed CRC transcription factors in the wider context of cancer CRC models.

Indexed as

Bromodomain Containing ProteinsCell Cycle ProteinsCell LineageCell Line, TumorChromatinEnhancer Elements, GeneticEpigenesis, GeneticGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansNeoplasmsProtein BindingTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsChromatinTranscription Factorscell identitycore regulatory circuitryliquid and solid cancerssuper-enhancers

Identifiers

PMID32634370
PMCPMC7574545
OpenAlexW3040857431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.